natgillin/translations-raw huggingface dataset:
Talk to your doctor before taking Odefsey: • If you have liver problems or a history of liver disease, including hepatitis.
• Ako imate tegobe s jetrom ili imate bolest jetre u povijesti bolesti, uključujući hepatitis.
Croscarmellose sodium Lactose (as monohydrate) Magnesium stearate Microcrystalline cellulose Polysorbate 20
Jezgra tablete umrežena karmelozanatrij laktoza (u obliku hidrata) magnezijev stearat mikrokristalična celuloza polisorbat 20
Co-administration of Odefsey and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Uočeno je da istodobna primjena Odefsey i lijekova koji induciraju CYP3A smanjuje koncentracije rilpivirina u plazmi što bi potencijalno moglo dovesti do gubitka virološkog odgovora na lijek Odefsey (vidjeti dio 4.3) i moguće rezistencije na rilpivirin i na skupinu NNRTI.
Through Week 96, in patients who switched to Odefsey from emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) or efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) (Studies GS-US-366-1216 and GS-US-366-1160; n = 754), no treatment-emergent resistance-associated mutations were detected.
Do 96. tjedna, u bolesnika koji su s emtricitabina/rilpivirina/tenofovirdizoproksilfumarata (FTC/RPV/TDF) ili efavirenza/emtricitabina/tenofovirdizoproksilfumarata (EFV/FTC/TDF) prebačeni na Odefsey (Ispitivanja GS-US-366-1216 i GS-US-366-1160; n = 754), nisu ustanovljene nikakve mutacije povezane s rezistencijom nastale tijekom liječenja.
polymerases α, β and mitochondrial DNA polymerase γ.
Rilpivirin ne inhibira polimeraze α, β humane stanične DNK i polimerazu γ mitohondrijske DNK.
d There were 10 new virologic failures between the Week 48 primary analysis and Week 96 (3 patients with baseline viral load ≤ 100,000 copies/mL and 7 patients with baseline viral load > 100,000 copies/mL).
d Bilo je 10 novih viroloških neuspjeha između primarne analize 48. tjedna i 96. tjedna (3 bolesnika s početnim virusnim opterećenjem ≤ 100 000 kopija/ml i 7 bolesnika s početnim virusnim opterećenjem > 100 000 kopija/ml).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine + tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
+ tenofovirdizoproksilfumaratom bile su mučnina (9%), omaglica (8%), abnormalni snovi (8%), glavobolja (6%), proljev (5%) i nesanica (5%).
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food Do not chew, crush or split the tablet.
Adolescenti u dobi od 12 godina i stariji, koji imaju tjelesnu težinu najmanje 35 kg: jedna tableta svaki dan, s hranom
In patients receiving rilpivirine hydrochloride in combination with FTC/TDF in Phase 3 studies (TMC278-C209 and TMC278-C215 pooled data), most HIV-1 isolates with emergent phenotypic resistance to rilpivirine had cross-resistance to at least one other NNRTI (28/31).
U bolesnika koji primaju rilpivirinklorid u kombinaciji s FTC/TDF u ispitivanjima faze 3 (objedinjeni podaci TMC278-C209 i TMC278-C215), najveći broj HIV-1 izolata s novonastalom fenotipskom rezistencijom na rilpivirin imalo je križnu rezistenciju na najmanje jedan drugi NNRTI (28/31).
The active substances are emtricitabine, rilpivirine and tenofovir alafenamide.
Djelatne tvari su emtricitabin, rilpivirin i tenofoviralafenamid.
Recommendation concerning co-administration with Odefsey
Preporuka za istodobnu primjenu s lijekom Odefsey
At baseline, median plasma HIV-1 RNA was 4.7 log10 copies/mL, median CD4+ cell count was 456 cells/mm3 (range 95 to 1,110), and median CD4+% was 23% (range 7-45).
Na početku je medijan HIV-1 RNK u plazmi bio 4,7 log10 kopija/ml, medijan broja CD4+ stanica bio je 456 stanica/mm3 (raspon 95 do 1110) i medijan postotka CD4+ stanica bio je 23% (raspon 7-45).
In a study of emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in HIV-1 infected adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis, efficacy was maintained through 48 weeks but emtricitabine exposure was significantly higher than in patients with normal renal function.
U ispitivanju fiksne kombinacije emtricitabina i tenofoviralafenamida s elvitegravirom i kobicistatom u jednoj tableti (E/C/F/TAF) u odraslih zaraženih virusom HIV-1 sa završnim stadijem bolesti bubrega (procijenjeni CrCl < 15 ml/min) na kroničnoj hemodijalizi, djelotvornost je bila održana tijekom 48 tjedana, ali izloženost emtricitabinu bila je značajno veća nego u bolesnika s normalnom funkcijom bubrega.
NARCOTIC ANALGESICS Methadone (60-100 mg once daily, individualised dose)/ Rilpivirine
Metadon (60-100 mg jedanput na dan, individualizirana doza)/
Tenofovir alafenamide is rapidly absorbed following oral administration, with peak plasma concentrations occurring at 15-45 minutes post-dose.
Nakon peroralne primjene, tenofoviralafenamid se brzo apsorbira i postiže vršne koncentracije u plazmi 15-45 minuta nakon doziranja.
• If you are currently taking any of the following medicines: - carbamazepine, oxcarbazepine, phenobarbital and phenytoin (used to treat epilepsy and prevent seizures) - rifabutin, rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
• Ako trenutno uzimate neki od sljedećih lijekova: karbamazepin, okskarbazepin, fenobarbital i fenitoin (koristi se u liječenju epilepsije i za sprječavanje napada) rifabutin, rifampicin i rifapentin (koriste se za liječenje nekih bakterijskih infekcija, kao što je tuberkuloza) - omeprazol, dekslanzoprazol, lanzoprazol, rabeprazol, pantoprazol i esomeprazol (koriste se za sprječavanje i liječenje čireva želuca i dvanaesnika, žgaravice, gastroezofagealne refluksne bolesti)
The safety assessment of rilpivirine is based on Week 48 data from one single-arm open-label study (TMC278-C213) in 36 paediatric patients 12 to < 18 years and weighing at least 32 kg. No patients discontinued rilpivirine due to adverse reactions.
Sigurnosno ocjenjivanje rilpivirina utemeljeno je na podacima 48. tjedna iz otvorenog ispitivanja s jednom skupinom (TMC278-C213) u 36 pedijatrijskih bolesnika u dobi od 12 do < 18 godina s tjelesnom težinom od najmanje 32 kg.
Intracellular tenofovir is subsequently phosphorylated to the active metabolite tenofovir diphosphate.
Unutar stanice se tenofovir naknadno fosforilira u aktivan metabolit tenofovirdifosfat.
No new adverse reactions were identified through Week 96 in 2 clinical studies of virologically suppressed patients who switched from emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) to Odefsey (Study GS-US-366-1216) or from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to Odefsey (Study GS-US-366-1160).
Nove nuspojave nisu ustanovljene do 96. tjedna u dva klinička ispitivanja u bolesnika u kojih je virus bio suprimiran, a koji su prebačeni s emtricitabina/rilpivirina/tenofovirdizoproksilfumarata (FTC/RPV/TDF) na Odefsey (Ispitivanje GS-US-366-1216) ili s efavirenza/emtricitabina/tenofovirdizoproksilfumarata (EFV/FTC/TDF) na Odefsey (Ispitivanje GS-US-366-1160).
The pharmacokinetics of rilpivirine in antiretroviral-naïve HIV-1 infected paediatric patients 12 to < 18 years of age receiving rilpivirine 25 mg once daily was comparable to that in treatment-naïve HIV-1 infected adults receiving rilpivirine 25 mg once daily.
Farmakokinetika rilpivirina u pedijatriskih bolesnika u dobi od 12 do < 18 godina, zaraženih virusom HIV-1 koji prethodno nisu bili antiretrovirusni liječeni i koji su primali rilpivirin od 25 mg jedanput na dan mogla se usporediti s onom u odraslih bolesnika zaraženih virusom HIV-1 koji su primali rilpivirin od 25 mg jedanput na dan.
(n = 316)
ODE (n = 316)
The safety of emtricitabine + tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [E/C/F/TAF]) was evaluated in 72 HIV/HBV co-infected patients receiving treatment for HIV in an open-label clinical study (GS-US-292-1249), through Week 48, in which patients were switched from another antiretroviral regimen (which included TDF in 69 of 72 patients) to E/C/F/TAF.
Bolesnici s istodobnom infekcijom HIV-om i HBV-om Sigurnost emtricitabina + tenofoviralafenamida u kombinaciji s elvitegravirom i kobicistatom u obliku tablete s fiksnom kombinacijom (elvitegravir/kobicistat/emtricitabin/tenofoviralafenamid [E/C/F/TAF]) procijenjena je u 72 bolesnika koji su bili zaraženi HIV-om/HBV-om te koji su u tom trenutku liječili HIV infekciju u otvorenom kliničkom Ispitivanju (GS-US-292-1249) tijekom 48. tjedna, u kojem su bolesnici bili prebačeni s drugog antiretrovirusnog režima (koji je uključivao TDF u 69 od 72 bolesnika) na E/C/F/TAF.
In Study GS-US-366-1160, the efficacy and safety of switching from EFV/FTC/TDF to Odefsey were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults.
Ispitivanju GS-US-366-1160, djelotvornost i sigurnost prebacivanja s EFV/FTC/TDF na Odefsey procijenjene su u randomiziranom, dvostruko slijepom ispitivanju u odraslih bolesnika zaraženih virusom HIV-1 u kojih je virus bio suprimiran.
If you are taking an antacid, take it at least 2 hours before or at least 4 hours after Odefsey.
Ako uzimate antacid, uzmite ga najmanje 2 sata prije ili najmanje 4 sata nakon uzimanja lijeka Odefsey.
ANTIDIABETICS Metformin (850 mg single dose)/ Rilpivirine
Metformin (jedna doza od 850 mg)/rilpivirin
Simeprevir (150 mg once daily)/ Rilpivirine
Simeprevir (150 mg jedanput na dan)/rilpivirin
Changes in serum creatinine for rilpivirine-containing regimens The pooled data from the Phase 3 TMC278-C209 and TMC278-C215 studies of treatment-naïve patients also demonstrate that serum creatinine increased and estimated glomerular filtration rate (eGFR) decreased over 96 weeks of treatment with rilpivirine.
Promjene serumskog kreatinina za režime koji sadrže rilpivirin Objedinjeni podaci iz Ispitivanja TMC278-C209 i TMC278-C215 faze 3 bolesnika koji prethodno nisu bili liječeni, također demonstriraju povećanje serumskog kreatinina i smanjenje procijenjene brzine glomerularne filtracije (eGFR) tijekom 96 tjedana liječenja rilpivirinom.
Sofosbuvir (400 mg once daily)/ Rilpivirine (25 mg once daily)
Sofosbuvir (400 mg jedanput na dan)/rilpivirin (25 mg jedanput na dan)
How to take Odefsey
Kako uzimati lijek Odefsey
ORAL CONTRACEPTIVES Ethinylestradiol (0.035 mg once daily)/ Rilpivirine
Etinilestradiol (0,035 mg jedanput na dan)/rilpivirin
Co-administration of Odefsey with proton pump inhibitors has been observed to decrease the plasma concentrations of rilpivirine (due to an increase in gastric pH) which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Uočeno je da istodobna primjena lijeka Odefsey i inhibitora protonske pumpe smanjuje koncentracije rilpivirina u plazmi (zbog porasta želučanih pH-vrijednosti) što bi potencijalno moglo dovesti do gubitka virološkog odgovora na lijek Odefsey (vidjeti dio 4.3) i moguće rezistencije na rilpivirin i na skupinu NNRTI.
If a patient misses a dose of Odefsey by more than 12 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Ako je od propuštene doze prošlo više od 12 sati, bolesnik ne treba uzeti propuštenu dozu nego jednostavno nastaviti uzimati doze prema uobičajenom rasporedu.
If a patient vomits more than 4 hours after taking Odefsey they do not need to take another dose of Odefsey until the next regularly scheduled dose.
Ako bolesnik povraća nakon što je prošlo 4 sata od uzimanja lijeka Odefsey, ne mora uzeti još jednu dozu lijeka Odefsey prije sljedeće doze prema redovitom raspredu.
Effects on medicinal product levels.
Lijekovi prema terapijskim područjima Učinci na razinu lijekova.
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 2,396 patients received emtricitabine + tenofovir alafenamide given with elvitegravir + cobicistat as a fixed-dose combination tablet, pooled data from 686 patients who received rilpivirine 25 mg once daily in combination with other antiretroviral medicinal products in the controlled studies TMC278-C209 and TMC278-C215, 754 patients who received Odefsey in Studies GS-US-366-1216 and GS-US-366-1160, and post-marketing experience.
+ tenofoviralafenamid davanim s elvitegravirom + kobicistatom u obliku tablete s fiksnom kombinacijom doza, objedinjenim podacima 686 bolesnika koji su u kontroliranim ispitivanjima TMC278-C209 i TMC278-C215 primali 25 mg rilpivirina jedanput na dan u kombinaciji s drugim antiretrovirusnim lijekovima, 754 bolesnika koji su primali Odefsey u ispitivanjima GS-US-366-1216 i GS-US-366-1160 i iz razdoblja nakon stavljanja u promet.
How to store Odefsey
Kako čuvati lijek Odefsey
At Week 48, 81.8% (45/55 patients) maintained HIV-1 RNA < 50 copies/mL after switching to E/C/F/TAF.
U 48. tjednu, HIV-1 RNK < 50 kopija/ml zadržala se u 81,8% (45/55 bolesnika) nakon prebacivanja na E/C/F/TAF.
GLUCOCORTICOIDS Dexamethasone (systemic, except for single dose use)
Deksametazon (sistemska primjena, osim za primjenu jednokratne doze)
In Study GS-US-366-1216, the mean change from baseline in CD4+ cell count at Week 96 was 12 cells/mm3 in patients who switched to Odefsey and 16 cells/mm3 in those who remained on FTC/RPV/TDF.
Ispitivanju GS-US-366-1216, srednja vrijednost promjene u odnosu na početni broj stanica CD4+ u 96. tjednu bila je 12 stanica/mm3 u bolesnika koji su prebačeni na Odefsey i 16 stanica/mm3 u onih koji su ostali na FTC/RPV/TDF.
In Study GS-US-366-1160, the mean change from baseline in CD4+ cell count at Week 96 was 12 cells/mm3 in patients who switched to Odefsey and 6 cells/mm3 in those who stayed on EFV/FTC/TDF.
U Ispitivanju GS-US-366-1160, srednja vrijednost promjene u odnosu na početni broj stanica CD4+ u 96. tjednu bila je 12 stanice/mm3 u bolesnika koji su prebačeni na Odefsey i 6 stanica/mm3 u onih koji su ostali na EFV/FTC/TDF.
The pharmacokinetics of rilpivirine in paediatric patients < 12 years of age is under investigation.
Farmakokinetika rilpivirina u pedijatrijskih bolesnika u dobi
Median plasma HIV-1 RNA was 5.0 log10 copies/mL and median CD4+ cell count was 255 cells/mm3.
Medijan HIV-1 RNK u plazmi bio je 5,0 log10 kopija/ml, medijan broja CD4+ stanica bio je 255 stanica/mm3.
Resistance testing and/or historical resistance data should guide the use of Odefsey (see section 5.1).
Liječenje lijekom Odefsey treba se voditi na temelju ispitivanja rezistencije i/ili podataka o rezistenciji iz povijesti bolesti (vidjeti dio 5.1).
In a study of virologically suppressed patients switching from EFV/FTC/TDF to Odefsey (Study GS-US-366-1160), decreases from baseline were observed in the fasting values of total cholesterol and HDL-cholesterol in the Odefsey arm; no clinically relevant changes from baseline in median fasting values for total cholesterol to HDL-cholesterol ratio, direct LDL-cholesterol or triglycerides were observed in either treatment arm at Week 96.
U ispitivanju s virološki suprimiranim bolesnicima koji su prebačeni s EFV/FTC/TDF na Odefsey (Ispitivanje GS-US-366-1160), u skupini koja je primala Odefsey opažena su smanjenja u odnosu na početnu vrijednost u vrijednostima ukupnog kolesterola i HDL kolesterola natašte; nikakve klinički relevantne promjene u odnosu na početne vrijednosti nisu opažene za medijan vrijednosti omjera ukupnog kolesterola i HDL kolesterola, direktnog LDL kolesterola ili triglicerida natašte ni u jednoj liječenoj skupini u 96. tjednu.
If you vomit less than 4 hours after taking Odefsey, take another tablet with food.
Ako povratite unutar 4 sata od uzimanja lijeka Odefsey, uzmite drugu tabletu s hranom.
Co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH).
Istodobna primjena može prouzročiti značajna smanjenja koncentracije rilpivirina u plazmi (smanjena apsorpcija, povećanje zelučanih pH-vrijednosti).
If the patient vomits within 4 hours of taking Odefsey another tablet should be taken with food.
Ako bolesnik povrati unutar 4 sata od uzimanja lijeka Odefsey, mora uzeti drugu tabletu s hranom.
In Study GS-US-292-1825, the efficacy and safety of E/C/F/TAF were evaluated in a single arm, open-label clinical study in which 55 HIV-1 infected adults with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis for at least 6 months before switching to E/C/F/TAF FDC tablet.
U otvorenom kliničkom ispitivanju GS-US-292-1825, djelotvornost i sigurnost E/C/F/TAF procijenjene su u jednoj skupini od 55 odraslih osoba zaraženih virusom HIV-1 sa završnim stadijem bolesti bubrega (eGFRCG < 15 ml/min) i na kroničnoj hemodijalizi tijekom najmanje 6 mjeseci prije prebacivanja na E/C/F/TAF tablete.
If you are taking an H2-antagonist, take it at least 12 hours before or at least 4 hours after Odefsey.
Ako uzimate H2-antagonist, uzmite ga najmanje 12 sata prije ili najmanje 4 sata nakon uzimanja lijeka Odefsey.
What you need to know before you take Odefsey Do not take Odefsey:
Što morate znati prije nego počnete uzimati lijek Odefsey
The combination of Odefsey with these macrolide antibiotics may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Kombinacija lijeka Odefsey s ovim makrolidnim antibioticima može uzrokovati povećanje koncentracije rilpivirina (inhibicija CYP3A) i tenofoviralafenamida (inhibicija P-gp) u plazmi.
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells,
Antivirusna aktivnost tenofoviralafenamida na laboratorijske i kliničke izolate virusa HIV-1 podtipa B procijenjena je na limfoblastoidnim staničnim linijama, PBMC-ovima, primarnim monocitnim/makrofagnim stanicama i CD4+ T-limfocitima.
AUC: ↓ 5% Cmin: ↓ 7% Cmax: ↓ 3%
AUC: ↓ 5% Cmax: ↓ 7% Cmax: ↓ 3%
In a study of virologically suppressed patients switching from FTC/RPV/TDF to Odefsey (Study GS-US-366-1216), increases from baseline were observed in fasting values of total cholesterol, direct LDL-cholesterol, HDL-cholesterol, and triglycerides in the Odefsey arm; and no clinically relevant changes from baseline in median fasting values for total cholesterol to HDL-cholesterol ratio were observed in either treatment arm at Week 96.
U ispitivanju s virološki suprimiranim bolesnicima koji su prebačeni s FTC/RPV/TDF na Odefsey (Ispitivanje GS-US-366-1216), u skupini koja je primala Odefsey opažena su povećanja u odnosu na početnu vrijednost u vrijednostima ukupnog kolesterola, direktnog LDL kolesterola, HDL kolesterola i triglicerida natašte; nikakve klinički relevantne promjene u odnosu na početne vrijednosti nisu opažene za medijan vrijednosti omjera ukupnog kolesterola i HDL kolesterola natašte ni u jednoj liječenoj skupini u 96. tjednu.
Rifampicin:
Rilpivirin:
The mean baseline CD4+ cell count was 709 cells/mm3 (range 104-2,527).
Srednja vrijednost početnog broja CD4+ stanica iznosila je 709 stanica/mm3 (raspon 104−2527).
25-O-desacetyl-rifabutin:
25-O-desacetilrifabutin: AUC: ↔
Ketoconazole (400 mg once daily)/ Rilpivirine1
Ketokonazol (400 mg jedanput na dan)/rilpivirin1
There were no new safety issues identified in patients with end stage renal disease on chronic haemodialysis receiving emtricitabine + tenofovir alafenamide, given with elvitegravir + cobicistat as a fixed-dose combination tablet (see section 4.8).
Nije bilo utvrđenih novih sigurnosnih pitanja u bolesnika sa završnim stadijem bolesti bubrega na kroničnoj hemodijalizi koji su primali fiksnu kombinaciju emtricitabina i tenofoviralafenamida s elvitegravirom i kobicistatom u jednoj tableti (vidjeti dio 4.8).
omeprazole, dexlansoprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole (used to prevent and treat stomach ulcers, heartburn, acid reflux disease) dexamethasone (a corticosteroid medicine used to treat inflammation and suppress the immune system) when taken by mouth or injected (except as a single dose treatment) products that contain St. John's wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety)
- karbamazepin, okskarbazepin, fenobarbital i fenitoin (koriste se u liječenju epilepsije i za sprječavanje napada) - rifabutin, rifampicin i rifapentin (koriste se za liječenje nekih bakterijskih infekcija, kao što je tuberkuloza) - omeprazol, dekslanzoprazol, lanzoprazol, rabeprazol, pantoprazol i esomeprazol (koriste se za sprječavanje i liječenje čireva želuca i dvanaesnika, žgaravice, gastroezofagealne refluksne bolesti) - deksametazon (kortikosteroidni lijek koji se koristi za liječenje upala i suprimiranje imunološkog sustava) kada se uzima na usta ili se ubrizgava (osim kod liječenja primjenom jednokratne doze) - proizvodi koji sadržavaju gospinu travu (Hypericum perforatum) (biljni lijek koji se primjenjuje za depresiju i tjeskobu)
Co-administration of ketoconazole is expected to increase plasma concentrations of tenofovir alafenamide (inhibition of P-gp).
Očekuje se da će istodobna primjena ketokonazola povisiti koncentracije tenofoviralafenamida (inhibicija P-gp) u plazmi.
Interaction not studied with any of the components of Odefsey.
Interakcija nije ispitana ni s jednom komponentom lijeka
headache1, 3, dizziness1, 3
glavobolja1,3, omaglica1,3
4 Adverse reaction identified through post-marketing surveillance of emtricitabine/rilpivirine/tenofovir disoproxil fumarate.
4 Nuspojava prepoznata tijekom praćenja lijeka emtricitabin/rilpivirin/tenofovirdizoproksilfumarat nakon stavljanja u promet.
Odefsey [Outer packaging only]
16. PODACI NA BRAILLEOVOM PISMU Odefsey [samo vanjsko pakiranje]
Sofosbuvir/Velpatasvir (400 mg/100 mg once daily)/ Rilpivirine2
Sofosbuvir/velpatasvir (400 mg/100 mg jedanput na dan)/rilpivirin2
Exposures of emtricitabine and tenofovir in 12 patients with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis who received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in Study GS-US-292-1825 were significantly higher than in patients with normal renal function.
CrCl < 15 ml/min) na kroničnoj hemodijalizi koji su primali emtricitabin + tenofoviralafenamid s elvitegravirom + kobicistatom u fiksnoj kombinaciji u tableti (E/C/F/TAF) u ispitivanju GS-US-292-1825 bila je značajno veća nego u bolesnika s normalnom funkcijom bubrega.
(n = 438)
ODE (n = 438)
0% (95% CI: -4.8% to 4.8%)
0% (95% CI: -4,8% do 4,8%)
AUC: ↔ Cmin: ↓ 15% Cmax: ↑ 35%
Atorvastatin AUC: ↔ Cmin: ↓ 15% Cmax: ↑ 35%
The median baseline plasma HIV-1 RNA was 4.8 log10 copies/mL, and the median baseline CD4+ cell count was 414 cells/mm3.
Medijan početne vrijednost HIV-1 RNK u plazmi bio je 4,8 log10 kopija/ml, medijan početnog broja CD4+ stanica bio je 414 stanica/mm3.
Each film-coated tablet contains 200 mg of emtricitabine, rilpivirine hydrochloride equivalent to 25 mg of rilpivirine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
Jedna filmom obložena tableta sadržava 200 mg emtricitabina, rilpivirinklorid što odgovara 25 mg rilpivirina i tenofoviralafenamidfumarat što odgovara 25 mg tenofoviralafenamida.
The mean baseline CD4+ cell count was 664 cells/mm3 (range 126-1,813).
Srednja vrijednost početnog broja CD4+ stanica iznosila je 664 stanica/mm3 (raspon: 126-1813).